Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Interdict Bio Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units, indicating that each pending matter is being treated as a separate technical entity by the patent office. This distribution suggests that the company's active applications may cover different aspects of biotechnology that fall under the jurisdiction of different specialized groups. REI TSANG SHIAO is the busiest examiner for the portfolio, currently overseeing 1 pending office action.
With 2 pending actions distributed across multiple examiners, the workload is evenly divided, with each examiner handling a single action. This requires the company to manage two separate prosecution tracks simultaneously, each with its own examiner and art unit standards. Practitioners should be prepared to address the specific requirements of 2 distinct art units within the Biotechnology & Pharmaceuticals sector. The lack of concentration in a single art unit or examiner means that the outcomes of the pending office actions are likely to be independent of one another.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18890690 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | SHIAO, REI TSANG | — |
| 18890292 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | YOUNGBLOOD, WILLIAM JUSTIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18890292 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | YOUNGBLOOD, WILLIAM JUSTIN | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18890690 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | SHIAO, REI TSANG | 1691 | §102§103§112 | Non-Final OA | — | Pending | Sep 19, 2024 |
| 18890292 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102§112 | Non-Final OA | — | Pending | Sep 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInterdict Bio Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Rei Tsang Shiao has the most, with 1 of Interdict Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
